Mark Rolfe

Bio

Mark is a Venture Partner and joined OrbiMed in 2025. Prior to joining OrbiMed, Mark was a Senior Vice President, Oncogenesis Thematic Research Center, at Bristol Myers Squibb, where he oversaw all targeted protein degradation research and early development efforts in hematology/oncology. His extended group discovered nine first-in-class/best-in-class protein degraders in a seven-year span, with three entering late-stage registrational trials. He has experience running research and early development teams in both large and medium-sized pharmaceutical companies (Millennium/Takeda, Facet Biotech, Celgene/Bristol Myers Squibb) and venture-backed start-ups (CSO at CytomX, Cleave Biosciences). Mark received his B.A. and M.A. from Oxford University and his Ph.D. from the Medical Research Council in London. He completed Post-Doctoral Fellowships at Cancer Research UK (CRUK/ICRF) in London and Columbia University College of Physicians and Surgeons in New York.